Enhanced Delayed-type Hypersensitivity and Diminished Immediate-type Hypersensitivity in Mice Lacking the Inducible VPAC(2) Receptor for Vasoactive Intestinal Peptide

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2001 Nov 8

PMID 11698667

Citations 44

Authors

E J Goetzl

J K Voice

S Shen

G Dorsam

Y Kong

K M West

C F Morrison

A J Harmar

Affiliations

Soon will be listed here.

Abstract

Vasoactive intestinal peptide (VIP) and its G protein-coupled receptors, VPAC(1)R and VPAC(2)R, are prominent in the immune system and regulate many aspects of T cell-dependent immunity. In mouse T cells, VPAC(1)R is expressed constitutively, whereas VPAC(2)R is induced by immune stimuli. VPAC(2)R-null (VPAC(2)R(-/-)) mice on a C57BL/6 background are shown here to have normal basic immune characteristics, including serum Ig concentrations, blood levels of all leukocytes, and spleen number of total T cells (CD3(+)) and T cells bearing CD4, CD8, and CD28. Hapten-evoked cutaneous delayed-type hypersensitivity (DTH) was significantly enhanced in VPAC(2)R-null mice compared with age- and sex-matched wild-type mice. In contrast, generation of IgE anti-hapten antibodies and active cutaneous anaphylaxis were > or =70% lower in VPAC(2)R-null mice than in wild-type controls. Cytokine production by splenic CD4(+) T cells, stimulated with adherent anti-CD3 plus anti-CD28 antibodies, revealed higher levels of IL-2 (mean = 3-fold) and IFN-gamma (mean = 3-fold), and lower levels of IL-4 (mean = one-fifth) in VPAC(2)R-null mice than wild-type controls. Loss of VIP-VPAC(2)R maintenance of the normal ratio of Th2/Th1 cytokines thus leads to a state of enhanced DTH and depressed immediate-type hypersensitivity, which may alter both host defense and susceptibility to immune-mediated diseases.

Citing Articles

Vasoactive Intestinal Peptide (VIP) and its Receptors in Adipose Tissue: Implications for Cold Stress Adaptation.

Korkmaz O, Saydam F, Dalkiran B, Degirmenci I, Tuncel N Cell Biochem Biophys. 2024; .

PMID: 39550744 DOI: 10.1007/s12013-024-01606-0.

Sensory neurons: An integrated component of innate immunity.

Deng L, Gillis J, Chiu I, Kaplan D Immunity. 2024; 57(4):815-831.

PMID: 38599172 PMC: 11555576. DOI: 10.1016/j.immuni.2024.03.008.

spp. utilize the type 3 secretion system to manipulate the VIP/VPAC2 signaling and promote colonization and persistence of the three classical in the lower respiratory tract.

First N, Pedreira-Lopez J, San-Silvestre M, Parrish K, Lu X, Gestal M Front Cell Infect Microbiol. 2023; 13:1111502.

PMID: 37065208 PMC: 10090565. DOI: 10.3389/fcimb.2023.1111502.

Vasoactive Intestinal Peptide (VIP) Protects Nile Tilapia () against Infection.

Zhang Z, Li Q, Huang Y, Xu Z, Chen X, Jiang B Int J Mol Sci. 2022; 23(23).

PMID: 36499231 PMC: 9738603. DOI: 10.3390/ijms232314895.

Immunomodulatory Role of Neuropeptides in the Cornea.

Puri S, Kenyon B, Hamrah P Biomedicines. 2022; 10(8).

PMID: 36009532 PMC: 9406019. DOI: 10.3390/biomedicines10081985.

References

Ichikawa S, Sreedharan S, Goetzl E, Owen R . Immunohistochemical localization of peptidergic nerve fibers and neuropeptide receptors in Peyer's patches of the cat ileum. Regul Pept. 1994; 54(2-3):385-95. DOI: 10.1016/0167-0115(94)90536-3. View

Xia M, Sreedharan S, Bolin D, Gaufo G, Goetzl E . Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther. 1997; 281(2):629-33. View

Ganea D . Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv Neuroimmunol. 1996; 6(1):61-74. DOI: 10.1016/s0960-5428(96)00007-1. View

Jabrane-Ferrat N, Pollock A, Goetzl E . Inhibition of expression of the type I G protein-coupled receptor for vasoactive intestinal peptide (VPAC1) by hammerhead ribozymes. Biochemistry. 2000; 39(32):9771-7. DOI: 10.1021/bi0008783. View

Hernanz A, Tato E, de la Fuente M, De Miguel E, Arnalich F . Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J Neuroimmunol. 1996; 71(1-2):25-30. DOI: 10.1016/s0165-5728(96)00118-x. View

Metwali A, Blum A, Li J, Elliott D, Weinstock J . IL-4 regulates VIP receptor subtype 2 mRNA (VPAC2) expression in T cells in murine schistosomiasis. FASEB J. 2000; 14(7):948-54. DOI: 10.1096/fasebj.14.7.948. View

Sreedharan S, Patel D, Xia M, Ichikawa S, Goetzl E . Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways. Biochem Biophys Res Commun. 1994; 203(1):141-8. DOI: 10.1006/bbrc.1994.2160. View

Gomariz R, Leceta J, Garrido E, Garrido T, Delgado M . Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. Regul Pept. 1994; 50(2):177-84. DOI: 10.1016/0167-0115(94)90033-7. View

Martinez C, Delgado M, Gomariz R, Ganea D . Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J Immunol. 1996; 156(11):4128-36. View

10.

Dorsam G, Voice J, Kong Y, Goetzl E . Vasoactive intestinal peptide mediation of development and functions of T lymphocytes. Ann N Y Acad Sci. 2001; 921:79-91. DOI: 10.1111/j.1749-6632.2000.tb06953.x. View

11.

ODorisio M, Odorisio T, Shah M, Karacay B . Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol. 2001; 166(4):2522-30. DOI: 10.4049/jimmunol.166.4.2522. View

12.

Bellinger D, Lorton D, Brouxhon S, Felten S, Felten D . The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol. 1996; 6(1):5-27. DOI: 10.1016/s0960-5428(96)00008-3. View

13.

Delgado M, Martinez C, Leceta J, Gomariz R . Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. Neuroimmunomodulation. 1999; 6(1-2):97-107. DOI: 10.1159/000026369. View

14.

Delgado M, Martinez C, Johnson M, Gomariz R, Ganea D . Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol. 1996; 68(1-2):27-38. DOI: 10.1016/0165-5728(96)00063-x. View

15.

Mathew R, Cook G, Blum A, Metwali A, Felman R, Weinstock J . Vasoactive intestinal peptide stimulates T lymphocytes to release IL-5 in murine schistosomiasis mansoni infection. J Immunol. 1992; 148(11):3572-7. View

16.

Gourlet P, VANDERMEERS A, Vertongen P, RATHE J, De Neef P, Cnudde J . Development of high affinity selective VIP1 receptor agonists. Peptides. 1997; 18(10):1539-45. DOI: 10.1016/s0196-9781(97)00228-3. View

17.

Goetzl E, Patel D, Kishiyama J, Smoll A, Turck C, Law N . Specific recognition of the human neuroendocrine receptor for vasoactive intestinal peptide by anti-peptide antibodies. Mol Cell Neurosci. 1994; 5(2):145-52. DOI: 10.1006/mcne.1994.1016. View

18.

Sreedharan S, Huang J, Cheung M, Goetzl E . Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci U S A. 1995; 92(7):2939-43. PMC: 42334. DOI: 10.1073/pnas.92.7.2939. View

19.

KALTREIDER H, Ichikawa S, Byrd P, Ingram D, Kishiyama J, Sreedharan S . Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am J Respir Cell Mol Biol. 1997; 16(2):133-44. DOI: 10.1165/ajrcmb.16.2.9032120. View

20.

Voice J, Dorsam G, Lee H, Kong Y, Goetzl E . Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 2001; 15(13):2489-96. DOI: 10.1096/fj.01-0671com. View